The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis
|
|---|---|
| Published in |
Frontiers in oncology, October 2021
|
| DOI | 10.3389/fonc.2021.765608 |
| Pubmed ID | |
| Authors |
Anne Zaremba, Rafaela Kramer, Viola De Temple, Stefanie Bertram, Martin Salzmann, Anja Gesierich, Lydia Reinhardt, Barouyr Baroudjian, Michael M. Sachse, Gunhild Mechtersheimer, Douglas B. Johnson, Alison M. Weppler, Lavinia Spain, Carmen Loquai, Milena Dudda, Claudia Pföhler, Adriana Hepner, Georgina V. Long, Alexander M. Menzies, Matteo S. Carlino, Céleste Lebbé, Tomohiro Enokida, Makoto Tahara, Paul J. Bröckelmann, Thomas Eigentler, Katharina C. Kähler, Ralf Gutzmer, Carola Berking, Selma Ugurel, Nadine Stadtler, Antje Sucker, Jürgen C. Becker, Elisabeth Livingstone, Friedegund Meier, Jessica C. Hassel, Dirk Schadendorf, Maher Hanoun, Lucie Heinzerling, Lisa Zimmer |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 11% |
| United Kingdom | 1 | 11% |
| Portugal | 1 | 11% |
| Unknown | 6 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 4 | 44% |
| Members of the public | 4 | 44% |
| Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 19 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 16% |
| Professor | 1 | 5% |
| Other | 1 | 5% |
| Professor > Associate Professor | 1 | 5% |
| Student > Postgraduate | 1 | 5% |
| Other | 0 | 0% |
| Unknown | 12 | 63% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 2 | 11% |
| Medicine and Dentistry | 2 | 11% |
| Immunology and Microbiology | 1 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Unknown | 13 | 68% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 March 2022.
All research outputs
#6,910,760
of 26,550,749 outputs
Outputs from Frontiers in oncology
#2,336
of 23,253 outputs
Outputs of similar age
#127,460
of 447,960 outputs
Outputs of similar age from Frontiers in oncology
#123
of 1,509 outputs
Altmetric has tracked 26,550,749 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 23,253 research outputs from this source. They receive a mean Attention Score of 3.2. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,960 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 1,509 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.